EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Modification‐Selective Inhibition of Succinate Dehydrogenase a Enables Tumor‐Restricted Mitochondrial Modulation

Kaikai Xu, Lulu Kong, Kebin Ye, Xinlu Bao, Haowen Liu, Ning Wang iD, Yongming Deng iD, Wei Wang, Shaohua Wei, Lin Zhou iD

Advanced Science · 2026-11 · 13 (62)

DOI: 10.1002/advs.77046 ↗

At a glance

Journal article in Advanced Science, published online on 2026-08-19. Written by Kaikai Xu and 9 co-authors. Institution: College of Chemistry and Materials Science, Jiangsu Key Laboratory of Bio-functional Materials, Jiangsu Collaborative Innovation Centre of Biomedical…. Major MEDLINE topics: Succinate Dehydrogenase, Mitochondria, Urinary Bladder Neoplasms, Enzyme Inhibitors. 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Succinate dehydrogenase (SDH, complex II) connects the tricarboxylic acid (TCA) cycle to the electron transport chain (ETC), maintaining mitochondrial energy homeostasis. Selective SDH inhibition in diseased tissue has remained challenging due to the highly conserved catalytic architecture across normal tissues. Here, we reveal that SDH catalytic activity depends on the acetylation state of its catalytic subunit A (SDHA): the non‐acetylated form is catalytically active but exhibits fragile homeostasis in bladder cancer, contrasting with its robust maintenance in normal cells. Guided by this insight, we designed ZPI‐3, a conformationally optimized inhibitor that selectively engages the non‐acetylated SDHA, suppressing tumor SDH activity and growth while sparing normal cells. In orthotopic NMIBC models, ZPI‐3 outperforms mitomycin‐C. Differential SDH responses to ZPI‐3 in clinical specimens further suggest its potential for patient stratification and precision therapy. These findings establish modification‐selective inhibition as a paradigm for tumor‐selective mitochondrial modulation.

Subjects

MeSH terms (MEDLINE)

Succinate DehydrogenaseMitochondriaUrinary Bladder NeoplasmsEnzyme InhibitorsHumansAnimalsMiceCell Line, Tumor

Author keywords

non‐acetylated statephthalocyanineselective regulationsuccinate dehydrogenase

Substances

Succinate DehydrogenaseEnzyme Inhibitors

Authors and institutions

  • College of Chemistry and Materials Science, Jiangsu Key Laboratory of Bio-functional Materials, Jiangsu Collaborative Innovation Centre of Biomedical Functional Materials, Nanjing Normal University, Nanjing, China.
  • School of Science, Key Laboratory of High Performance Scientific Computation, Xihua University, Chengdu, China.
  • Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.
  • School of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China.

ORCID profiles: Ning Wang, Yongming Deng, Lin Zhou

Funding

  • National Natural Science Foundation of China

Cite

APA

Xu, K., Kong, L., Ye, K., Bao, X., Liu, H., Wang, N., Deng, Y., Wang, W., Wei, S., & Zhou, L. (2026). Modification‐Selective Inhibition of Succinate Dehydrogenase a Enables Tumor‐Restricted Mitochondrial Modulation. Advanced Science, 13(62). https://doi.org/10.1002/advs.77046

Vancouver

Xu K, Kong L, Ye K, Bao X, Liu H, Wang N, et al. Modification‐Selective Inhibition of Succinate Dehydrogenase a Enables Tumor‐Restricted Mitochondrial Modulation. Advanced Science. 2026;13(62). doi:10.1002/advs.77046

BibTeX
@article{Xu2026,
  author = {Xu, Kaikai and Kong, Lulu and Ye, Kebin and Bao, Xinlu and Liu, Haowen and Wang, Ning and Deng, Yongming and Wang, Wei and Wei, Shaohua and Zhou, Lin},
  title = {Modification‐Selective Inhibition of Succinate Dehydrogenase a Enables Tumor‐Restricted Mitochondrial Modulation},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {62},
  doi = {10.1002/advs.77046}
}
Start for free →